Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000391641 | SCV000330101 | pathogenic | not provided | 2015-12-31 | criteria provided, single submitter | clinical testing | The c.509-1 G>T pathogenic variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The c.509-1 G>T splice site variant in the TPP1 gene destroys the canonical splice acceptor site in intron 5. It is predicted to cause abnormal gene splicing, either leading to an abnormal message that is subject to nonsense-mediated mRNA decay, or to an abnormal protein product if the message is used for protein translation. Additionally, variants at the same canonical splice acceptor site have been reported in Human Gene Mutation Database in association with late-infantile neuronal ceroid lipofuscinosis (Stenson et al., 2014). Therefore, c.509-1 G>T is considered to be a pathogenic variant. |
Counsyl | RCV000666428 | SCV000790719 | likely pathogenic | Neuronal ceroid lipofuscinosis 2 | 2017-04-06 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000391641 | SCV001381083 | pathogenic | not provided | 2023-06-29 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 280202). Disruption of this splice site has been observed in individuals with neuronal ceroid lipofuscinosis (PMID: 10330339). This variant is not present in population databases (gnomAD no frequency). This sequence change affects an acceptor splice site in intron 5 of the TPP1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in TPP1 are known to be pathogenic (PMID: 10330339). |
Revvity Omics, |
RCV000391641 | SCV004238766 | likely pathogenic | not provided | 2023-06-01 | criteria provided, single submitter | clinical testing |